Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2015 Financial Results on Thursday, October 29, 2015
October 21 2015 - 9:05AM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical
company focused on bringing innovative therapies to market for
people with renal disease, today announced that it will host a
conference call and webcast on Thursday, October 29, 2015 at 8:00
a.m. ET to discuss its third quarter 2015 financial results and
provide a review of the Auryxia™ (ferric citrate) launch.
In order to participate in the conference call,
please dial 1-844-253-5359 (U.S.), 1-815-680-5932 (international)
and refer to conference ID: 64671741. The call will be webcast live
with slides and accessible through the Investors section of the
company’s website at www.keryx.com for a period of 15 days after
the call.
Keryx will announce its financial results for this
period in a press release to be issued prior to the call.
About Keryx Biopharmaceuticals,
Inc.
Keryx Biopharmaceuticals, with offices in New York
and Boston, is focused on bringing innovative therapies to market
for patients with renal disease. In December 2014, the company
launched its first FDA-approved product, Auryxia™ (ferric citrate)
for the control of elevated serum phosphorus levels, or
hyperphosphatemia, in patients with chronic kidney disease (CKD) on
dialysis, in the United States. In January 2014, ferric
citrate was approved for the treatment of patients with all stages
of CKD in Japan, where it is being marketed as Riona® by Keryx's
Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co.
Ltd. In September 2015, the European Commission granted European
market authorization for Fexeric® (ferric citrate coordination
complex) for the control of hyperphosphatemia in adults with
non-dialysis and dialysis-dependent chronic kidney disease. For
more information about Keryx, please visit www.keryx.com
Keryx Biopharmaceuticals Contact:
Lora Pike
Senior Director, Investor Relations
T: 617.466.3511
lora.pike@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024